Trials / Completed
CompletedNCT00339872
Study Evaluating IMA-638 in Asthma
Randomized, Double-Blind, Placebo-Controlled, Sequential-Group, Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IMA-638 Administered Subcutaneously and Intravenously to Subjects With Asthma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety of, and blood drug levels for, single, ascending doses of IMA-638 in mild to moderate asthma subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IMA-638 |
Timeline
- Start date
- 2006-02-01
- Completion
- 2007-04-01
- First posted
- 2006-06-21
- Last updated
- 2007-12-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00339872. Inclusion in this directory is not an endorsement.